Structuring Collaborative Agreements in Life Sciences

Drafting Terms to Expand Product Lines, Reduce Costs and Risks, and Leverage and Protect Assets

Recording of a 90-minute premium CLE webinar with Q&A

This program is included with the Strafford CLE Pass. Click for more information.
This program is included with the Strafford All-Access Pass. Click for more information.

Conducted on Tuesday, February 21, 2017

Recorded event now available

or call 1-800-926-7926
Course Materials

This CLE course will provide guidance to counsel for companies in the life sciences industry for structuring collaborative agreements. The panel will discuss key considerations including allocation of risk, establishment of milestones and obligations, protection of IP rights, and termination of agreements.


Collaboration agreements can invigorate a life sciences companies’ success. When facing the expiration of key patents, companies can develop new R&D opportunities and resources for final-stage development, clinical trials, manufacturing and distribution of new products through strategic partnerships with others.

While collaborative agreements provide businesses with an avenue to access resources, create new products and bring them to market, reduce expenses, and allocate risk, they must be carefully structured to protect a company’s assets.

Counsel involved in developing collaboration agreements for businesses must understand the critical challenges involved in allocating risks, protecting IP rights and handling termination of agreements.

Listen as our authoritative panel examines the key considerations when structuring collaborative agreements, including terms addressing allocation of risk, establishment of party roles, milestones and obligations, protection of IP rights, and termination of agreements, among others. The panel will outline approaches and best practices for structuring the collaboration agreements for life science companies.



  1. Key considerations
  2. Contract terms
    1. Risk allocation
    2. Roles of parties
    3. Establishing milestones
    4. Party obligations
    5. Development and marketing
    6. IP rights
    7. Termination
  3. Best practices


The panel will review these and other key issues:

  • What considerations and potential pitfalls should counsel keep in mind when crafting collaborative agreements?
  • What are the key contract terms that should be included in life sciences collaborative agreements?
  • What approaches are most effective for assigning ownership and development rights?


Judith A. Hasko
Judith A. Hasko

Latham & Watkins

Ms. Hasko focuses on representing companies developing biotechnology, pharmaceutical, medical device and diagnostic...  |  Read More

Amy L. Toro
Amy L. Toro

Covington & Burling

Ms. Toro specializes in technology transactions, with particular emphasis on life science arrangements, such as...  |  Read More

Access Anytime, Anywhere

Strafford will process CLE credit for one person on each recording. All formats include course handouts.

To find out which recorded format will provide the best CLE option, select your state:

CLE On-Demand Video